Cleaved caspase‐3 expression is a potential prognostic factor for endometrial cancer with positive peritoneal cytology

Ogane, Naoki; Yasuda, Masanori; Kato, Hiroyuki; Kato, Tomomi; Yano, Mitsutake; Kameda, Yoichi; Kamoshida, Shingo

doi:10.1111/cyt.12550

Cited by 7 publications

(6 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Caspase-3, a cysteine protease, plays an important role in execution of apoptosis. The proteolytic cleaves pro-caspase-3, an inactive proenzyme, into its active form, called cleaved caspase-3, which is responsible for specific cleavage of large numbers of key cellular proteins involved in apoptosis [ 23 ]. In this study, we detected the role of GHR knockdown and sorafenib in caspase-3 activity.…”

Section: Resultsmentioning

confidence: 99%

GHR knockdown enhances the sensitivity of HCC cells to sorafenib

Gao

et al. 2020

Aging

View full text Add to dashboard Cite

Sorafenib is approved for treatment of advanced hepatocellular carcinoma (HCC) by the Drug Administration. However, the efficacy of sorafenib has become very limited because most tumors have developed resistance to this drug. In this study, we found that sorafenib stimulated GHR expression in HCC cell lines. Thus, GHR might be linked to sorafenib resistance. To verify this hypothesis, we researched the roles of GHR knockdown and sorafenib combination in cell viability, apoptosis, cycle, and migration. The results showed that GHR blockage enhanced sorafenib blocking of cell cycle progression, leading to inhibition of this drug on HCC cell viability, and the improved promoting ability of sorafenib on cell apoptosis. In addition, it was found that GHR knockdown enhanced sorafenib inhibition of cell migration. The synergistic antitumor effects of sorafenib and GHR knockdown combination may be attributed to inhibition of PI3K/AKT/ERK1/2 signaling pathway. In conclusion, the findings suggest that GHR knockdown enhances the sensitivity of HCC cells to sorafenib. and the inactivation of PI3K/AKT/ERK1/2 signaling pathway may be the underlying mechanisms. This highlights the absence of GHR as a promising way to enhance sorafenib efficacy in HCC.

show abstract

Section: Resultsmentioning

confidence: 99%

GHR knockdown enhances the sensitivity of HCC cells to sorafenib

Gao

et al. 2020

Aging

View full text Add to dashboard Cite

show abstract

“…Some previous studies have shown that preoperative neoadjuvant intraarterial chemotherapy can reduce the incidence of postoperative complications [20], but the effect 4…”

Section: Discussionmentioning

confidence: 99%

“…Some previous studies have shown that preoperative neoadjuvant intraarterial chemotherapy can reduce the incidence of postoperative complications [ 20 ], but the effect of this chemotherapy regimen on the adverse reactions of EC patients remains unclear. Therefore, reducing the incidence of adverse reactions of patients is the key to improve their quality of life.…”

Section: Discussionmentioning

confidence: 99%

Application of Jianpi Xiaoai Recipe Combined with Cisplatin and Adriamycin in the Treatment of Endometrial Cancer and Its Effect on Disease Control Rate

Ding

Wang

2021

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Objective. To explore the application of Jianpi Xiaoai recipe combined with cisplatin and Adriamycin in the treatment of endometrial cancer (EC) and its effect on the disease control rate (DCR). Methods. The data of 120 EC patients treated in People’s Hospital of Rizhao from February 2019 to February 2020 were retrospectively analyzed. They were equally split into experimental group and control group according to the order of admission. All patients were treated with neoadjuvant intra-arterial chemotherapy (continuous infusion of the uterine artery for 5 days before surgery, with 20 mg of cisplatin mixed with 2000 mg of normal saline and 10 mg of Adriamycin mixed with 500 ml of normal saline daily), while the experimental group was treated with Jianpi Xiaoai recipe at the same time to compare the short-term efficacy, immune function indexes, incidence of adverse reactions, and HEC-1-B (human endometrial adenocarcinoma cells) cell inhibition rates between the two groups. Results. The DCR and objective remission rate (ORR) in the experimental group were markedly higher compared with the control group ( P < 0.05). The immune function indexes after treatment were remarkably better in the experimental group than in the control group ( P < 0.05). Compared with the control group, the incidence of adverse reactions in the experimental group was notably lower ( P < 0.05), while the HEC-1-B inhibition rates after treatment were obviously higher ( P < 0.05). Conclusion. Jianpi Xiaoai recipe combined with cisplatin and Adriamycin can increase the HEC-1-B cell inhibition rate in EC patients, improve their immune function, reduce the possibility of adverse reactions, and enhance the therapeutic effect, which is worthy of clinical application and popularization.

show abstract

“…Targeted depletion of Ki67 gene in the mouse gut epithelium did not result in any cell proliferation deficiency. Furthermore, cleaved-caspase 3 detection is a better prognostic marker than Ki67 staining in colorectal and endometrial cancers [59 , 60] . Recently, suppression of TRAF6 expression through overexpression of miR-146a resulted in deregulation of tumor cell proliferation in non-small cell lung cancer [61] .…”

Section: Discussionmentioning

confidence: 99%